Compound profile
5-Amino-1MQ
EmergingAlso known as: 5-Amino-1-methylquinolinium
A small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in fat-cell metabolism and NAD+ regulation. Reduced fat mass in diet-induced-obese mice without affecting food intake, but has never been tested in a published human clinical trial.
Overview
5-Amino-1MQ is not a peptide but a small molecule, a quinolinium compound developed to selectively inhibit nicotinamide N-methyltransferase, an enzyme found at high levels in fat tissue that consumes the cell's nicotinamide and SAM (S-adenosyl-methionine) pools by converting nicotinamide into a byproduct called 1-methylnicotinamide. It is grouped with peptide research chemicals in fitness and longevity communities because it circulates through the same research-chemical marketplace and gets discussed for similar fat-loss and metabolic goals, even though its chemistry is unrelated.
The scientific interest in NNMT stems from research showing the enzyme is elevated in the fat tissue of obese animals and humans, and that blocking it in mice preserves more NAD+ and SAM within fat cells, nudging cellular energy metabolism away from fat storage. The original 2018 study identifying a selective, cell-permeable NNMT inhibitor, of which 5-Amino-1MQ is now the best known example, found it reduced fat mass in diet-induced-obese mice without reducing food intake or lean mass, a result that generated substantial follow-on interest in NNMT inhibition as a metabolic strategy.
What has not followed is any human clinical development. As of this review, no published human trial, safety or efficacy, has tested 5-Amino-1MQ in people. It is sold exclusively as an unregulated research chemical, and the weight-loss claims associated with it in commercial and social media contexts rest entirely on animal data extrapolated to a human use case that has never been formally studied.
Mechanism (plain language)
Selectively inhibits NNMT, an enzyme that consumes nicotinamide and SAM in fat cells; blocking it in animal studies preserves intracellular NAD+ and SAM pools, which is proposed to shift fat-cell metabolism away from lipogenesis and toward reduced fat storage.
How it works
NNMT sits at a metabolic crossroads inside fat cells, using a methyl group from SAM to convert nicotinamide, a form of vitamin B3 and a precursor to NAD+, into 1-methylnicotinamide, a compound the body then excretes. This reaction drains two resources fat cells otherwise use for energy metabolism and cellular repair, nicotinamide, which would otherwise replenish NAD+, and SAM, the cell's primary methyl donor used in a wide range of other reactions. Obese animals and humans tend to show elevated NNMT activity specifically in fat tissue, which researchers hypothesize contributes to a self-reinforcing cycle of fat storage.
By blocking NNMT, 5-Amino-1MQ is designed to interrupt that drain, preserving more nicotinamide and SAM inside fat cells. In diet-induced-obese mice, this translated into reduced fat mass and improved markers of insulin sensitivity without any change in how much the animals ate, suggesting the effect operates through altered fat-cell metabolism rather than appetite suppression, a mechanistically distinct approach from GLP-1 peptides and other appetite-based weight-loss compounds. Whether the same enzyme-inhibition effect and metabolic shift occurs to a meaningful degree in human fat tissue at achievable doses has not been tested.
What research suggests
Mouse studies consistently report reduced fat mass and improved insulin sensitivity with NNMT inhibition, without affecting food intake or lean mass, supporting the underlying biological hypothesis. There is no published human data of any kind, a gap the research-chemical marketing around this compound frequently glosses over.
Reported benefits
What studies, case reports, and the research literature describe, not guaranteed outcomes. The trials behind these findings are in the studies below.
Reduced fat mass without reduced food intake in mice
The foundational 2018 study reported that NNMT inhibition reduced fat mass and adipose NNMT activity in diet-induced-obese mice without changing how much the animals ate or reducing lean mass.
Improved insulin sensitivity markers in obese mice
Diet-induced-obese mice treated with NNMT inhibitors showed improved insulin sensitivity and normalized glucose tolerance approaching that of lean control animals, an effect not seen in NNMT knockout mice, supporting target specificity.
Uncertainties & risks
This compound has literally zero published human trials, safety or efficacy, despite being marketed for weight loss to people. Species differences in NNMT biology, dosing, and metabolism mean mouse results cannot be assumed to translate directly to humans, and long-term effects of sustained NNMT inhibition on methylation-dependent processes throughout the body are unexplored.
The most important thing to understand about 5-Amino-1MQ is the size of the gap between the animal science, which is genuinely interesting and methodologically reasonable, and the human marketing claims built on top of it, which currently have zero clinical trial support of any kind. Because NNMT and SAM sit at the intersection of numerous methylation reactions throughout the body, not just fat-cell metabolism, inhibiting the enzyme long-term raises open questions about broader downstream effects that simply have not been studied in any species beyond the specific metabolic endpoints researchers have measured so far. As an unregulated small molecule sold through research-chemical channels, sourcing, purity, and dosing consistency carry the same lack of oversight as unapproved peptides, without even the benefit of the decades of general safety experience some peptide hormone classes carry.
STACKD study summaries
Start with our in-house roundups, plain-language synthesis of the research, with primary sources cited at the bottom of each.
Primary sources
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.